This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS
by Sundeep Ganoria
President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
by Zacks Equity Research
NVAX and RNA are in the spotlight following Q3 results and study data, respectively.
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
by Zacks Equity Research
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Novavax to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA to remove the clinical hold on its two vaccine programs.
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax (NVAX) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the most recent trading session, Novavax (NVAX) closed at $10.07, indicating a -1.76% shift from the previous trading day.
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Novavax (NVAX) stood at $10, denoting a -1.19% change from the preceding trading day.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Novavax (NVAX) closed at $10.35 in the latest trading session, marking a +1.97% move from the prior day.
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
by Zacks Equity Research
VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.
Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
by Zacks Equity Research
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Novavax (NVAX) closed at $12.91, indicating a +1.77% shift from the previous trading day.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax (NVAX) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Novavax (NVAX) concluded the recent trading session at $14.42, signifying a -1.77% move from its prior day's close.
Novavax (NVAX) Moves 19.2% Higher: Will This Strength Last?
by Zacks Equity Research
Novavax (NVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, Novavax (NVAX) closed at $12.80, indicating a -0.85% shift from the previous trading day.
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
by Andrew Rocco
Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
by Zacks Equity Research
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.